So­bi's PhI­II gout win sets up a po­ten­tial ri­val­ry with fu­ture Am­gen as­set

Al­most three years af­ter Swedish Or­phan Biovit­rum — per­haps bet­ter known as So­bi — shelled out $100 mil­lion in cash to li­cense Se­lec­ta’s ex­per­i­men­tal drug for chron­ic re­frac­to­ry gout, the part­ners have clinched the Phase III da­ta they were striv­ing for.

The drug, SEL-212, met the pri­ma­ry end­point across two tri­als in a Phase III pro­gram, the com­pa­nies re­port­ed, mea­sured by the per­cent­age of pa­tients achiev­ing a re­sponse. They added that there was no dif­fer­ence in gout flares be­tween the treat­ment and place­bo arms at the six-month time point, a sec­ondary end­point, sug­gest­ing the drug was able to sup­press gout flares.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN